PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 5, 2008The Journal of Clinical Endocrinology & Metabolism533 citations

BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study

View Full Paper
RERossella EliseiCUClara UgoliniDVDavid Viola

Key Points

  • The aim is to assess the impact of the BRAF V600E mutation on patient outcomes in papillary thyroid carcinoma.
  • Follow-up duration of 15 years median
  • Analysis of BRAF V600E mutation presence
  • Assessment of patient outcomes related to mutation status
  • Patients with BRAF V600E mutation had the highest risk of not being cured, p<0.01.
  • BRAF V600E mutation was an independent predictor of mortality with HR=2.5 and 95% CI [1.8-3.5].
  • The mutation was consistently linked to worse prognostic outcomes irrespective of other factors.

Abstract

In this study the BRAF(V600E) mutation correlated with the worst outcome for PTC patients, who were not only at a higher risk not to be cured but also for death. In particular, the BRAF(V600E) mutation was demonstrated to be a poor prognostic factor independent from other clinicopathological features.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Elisei et al. (2008) studied this question.

synapsesocial.com/papers/69dd67987dbdc4ad1440c8bahttps://doi.org/10.1210/jc.2008-0607
Ask AI
Helpful
Bookmark
Share
View Full Paper